Compare Sanofi SA (SNY) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Value Index Fund ETF — how do they compare? Sanofi SA trades at $40.17 (market cap $95.18B), while Vanguard Value Index Fund ETF trades at $220.4 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 2.8× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| SNY | VTV | |
|---|---|---|
Market Cap | $95.18B | $262.40B |
Volume | 2,995,646 | 3,293,281 |
Sector | Health | — |
52-Week High | $52.34 | $227.51 |
52-Week Low | $39.51 | $182.86 |
Typical Hold Time | 94 Days | 142 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
VTV trades at $219.97, up 0.81% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces selling pressure from institutional indicators. Recent news highlights value stock outperformance in 2026, with VTV beating growth counterparts by significant margins. The fund offers a 2.3% dividend yield and low 0.03% expense ratio, attracting income-focused investors amid market rotation from growth to value strategies.
VTV presents a compelling value proposition with strong 2026 performance and institutional accumulation. However, technical weakness and long-term underperformance versus broad market indices pose risks. The ETF's low-cost structure and dividend yield support defensive positioning, but investors should weigh recent momentum against historical tracking error concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
